

Remarks

Claims 17 and 27 are pending in the current application.

Applicants have taken the opportunity of responding to the Restriction Requirement issued in the Official Communication dated May 18, 2011, to update the claim for benefit of priority of the present application.

In the Official Communication dated May 18, 2011, an election of species was required and no Groups were identified.

Although Applicants disagree with the Examiner's representations and reliance on Ashton *et al.* (US 4,493,843) in order to expedite prosecution, Applicants select for initial prosecution, the species of Example 1, which is 4-{5-[(3-methyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide. For the convenience of the Examiner, the named compounds in Claim 17 correspond, in order to the first 18 Examples in the specification. Example 20 is next, in order, followed by Example 19, the last named compound.

The Examiner has also imposed a requirement that Applicants identify the claims encompassing the selected species. In response, Applicants identify claims 17 and 27.

Applicants believe they have addressed each of the Examiner's requirements in the May 18, 2011, Office Communication. The Examiner is invited to contact the undersigned attorney by telephone if there are any questions about this submission or other issues that may be resolved in that manner.

Respectfully submitted,

/John C. Demeter/
John C. Demeter
Attorney for Applicants
Registration No. 30,167
Phone: 317-276-3785

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

May 20, 2011